Since acute exercise-induced increases in afterload may lead to RV dysfunction in PAH, we sought to determine whether E2 allows for superior RV adaptation after an acute exercise challenge. We studied echocardiographic, hemodynamic, structural, and biochemical markers of RV function in male and female rats with sugen/hypoxia (SuHx)-induced pulmonary hypertension, as well as in ovariectomized (OVX) SuHx females, with or without concomitant E2 repletion (75 g·kg Ϫ1 ·day Ϫ1 ) immediately after 45 min of treadmill running at 75% of individually determined maximal aerobic capacity (75% aerobic capacity reserve). Compared with males, intact female rats exhibited higher stroke volume and cardiac indexes, a strong trend for better RV compliance, and less pronounced increases in indexed total pulmonary resistance. OVX abrogated favorable RV adaptations, whereas E 2 repletion after OVX markedly improved RV function. E2's effects on pulmonary vascular remodeling were complex and less robust than its RV effects. Postexercise hemodynamics in females with endogenous or exogenous E 2 were similar to hemodynamics in nonexercised controls, whereas OVX rats exhibited more severely altered postexercise hemodynamics. E 2 mediated inhibitory effects on RV fibrosis and attenuated increases in RV collagen I/III ratio. Proapoptotic signaling, endothelial nitric oxide synthase phosphorylation, and autophagic flux markers were affected by E 2 depletion and/or repletion. Markers of impaired autophagic flux correlated with endpoints of RV structure and function. Endogenous and exogenous E 2 exerts protective effects on RV function measured immediately after an acute exercise challenge. Harnessing E 2's mechanisms may lead to novel RV-directed therapies.sugen/hypoxia; fibrosis; apoptosis; endothelial nitric oxide synthase; autophagy PULMONARY ARTERIAL HYPERTENSION (PAH) is a sexually dimorphic disease with a female-to-male ratio of up to 4:1 (3). Despite availability of 14 Food and Drug Administrationapproved medications, PAH remains a devastating, progressive, and incurable disease, evidenced by the disappointing 3-yr survival rate of only 55% (22). Even though both female sex and right ventricular (RV) function are major determinants of survival in PAH (5, 22, 23), no RV-or sex steroid-directed therapies exist. This is of importance, since women, despite being more prone to PAH development, exhibit better survival than male patients, a phenomenon attributed, at least in part, to better RV function in women (22,23,26,34,62).We and others demonstrated that the female sex hormone 17-estradiol (E 2 ) exerts protective effects on RV function in experimental PAH (11,36,37,60), findings that support observations made in healthy postmenopausal hormone replacement therapy users, where circulating E 2 levels correlate with better RV ejection fraction (61). Given the superior RV function of female PAH patients (23, 26), the exquisite sensitivity of the RV to increases in afterload (19), and the recent observation that exercise and physical activity...